Efficacy of First-Line Nivolumab Plus Chemotherapy in Advanced Gastric Cancer Stratified by PD-L1 Expression: A Real-World Comparison.

Cancers (Basel) · 2025 · PMC12651255 · PMID 41301077

Europe PMC DOI

hedged sentences

0.0450

closest p · 0.9× alpha

0.0450

boldest claim

The sentences

borderline significantp = 0.045actually significant

Furthermore, patients without liver metastasis demonstrated a significantly improved PFS (HR = 0.59, p = 0.027), and a borderline significant benefit was also seen in patients with liver metastasis (HR = 0.4, p = 0.045).

also in 11,409 other papers

did not reach statistical significanceno p-value reported

As expected, patients with PD-L1 CPS ≥ 5 showed a significant benefit in progression-free survival compared with those with CPS < 5, while overall survival differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.